Last reviewed · How we verify
Nalmefene Hydrochloride Hydrate
At a glance
| Generic name | Nalmefene Hydrochloride Hydrate |
|---|---|
| Sponsor | Otsuka Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Nausea
- Vomiting
- Tachycardia
- Hypertension
- Postoperative pain
- Fever
- Dizziness
- Headache
- Hypotension
- Vasodilation
- Chills
- Bradycardia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nalmefene Hydrochloride Hydrate CI brief — competitive landscape report
- Nalmefene Hydrochloride Hydrate updates RSS · CI watch RSS
- Otsuka Pharmaceutical Co., Ltd. portfolio CI